GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » ARYA Sciences Acquisition Corp II (NAS:ARYBU) » Definitions » PE Ratio without NRI

ARYA Sciences Acquisition II (ARYA Sciences Acquisition II) PE Ratio without NRI : (As of May. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is ARYA Sciences Acquisition II PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-05-06), ARYA Sciences Acquisition II's share price is $10.39. ARYA Sciences Acquisition II does not have enough years/quarters to calculate the EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2020. Therefore GuruFocus does not calculate PE Ratio without NRI at this moment.

ARYA Sciences Acquisition II's EPS without NRI for the six months ended in Jun. 2020 was $0.00.

As of today (2024-05-06), ARYA Sciences Acquisition II's share price is $10.39. ARYA Sciences Acquisition II does not have enough years/quarters to calculate the Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020. Therefore GuruFocus does not calculate PE Ratioat this moment.

ARYA Sciences Acquisition II's EPS (Diluted) for the six months ended in Jun. 2020 was $0.00.

ARYA Sciences Acquisition II's EPS (Basic) for the six months ended in Jun. 2020 was $0.00.


ARYA Sciences Acquisition II PE Ratio without NRI Historical Data

The historical data trend for ARYA Sciences Acquisition II's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYA Sciences Acquisition II PE Ratio without NRI Chart

ARYA Sciences Acquisition II Annual Data
Trend
PE Ratio without NRI

ARYA Sciences Acquisition II Semi-Annual Data
Feb20 Mar20 Jun20
PE Ratio without NRI At Loss At Loss At Loss

Competitive Comparison of ARYA Sciences Acquisition II's PE Ratio without NRI

For the Shell Companies subindustry, ARYA Sciences Acquisition II's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARYA Sciences Acquisition II's PE Ratio without NRI Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, ARYA Sciences Acquisition II's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where ARYA Sciences Acquisition II's PE Ratio without NRI falls into.



ARYA Sciences Acquisition II PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

ARYA Sciences Acquisition II's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=10.39/
=N/A

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


ARYA Sciences Acquisition II  (NAS:ARYBU) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


ARYA Sciences Acquisition II PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of ARYA Sciences Acquisition II's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


ARYA Sciences Acquisition II (ARYA Sciences Acquisition II) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
51 Astor Place, 10th Floor, New York, NY, USA, 10003
Website
ARYA Sciences Acquisition Corp II is a blank check company.
Executives
Joseph Edelman director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Adam Leo Stone director, officer: Chief Executive Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Michael Seth Altman director, officer: Chief Financial Officer C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Arya Sciences Holdings Ii 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Todd Wider director 4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219
Jake Bauer director C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Konstantin Poukalov officer: Chief Business Officer C/O KADMON HOLDINGS, LLC, 450 E 29TH STREET, NEW YORK NY 10016
Chad M Robins director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102